This is a material clinical catalyst for a commercial-stage company with an already-approved product. Watch for supplemental BLA submission timing (H2 2026) and potential FDA priority review status. The ATEV's infection rate advantage over catheters/AV fistulas strengthens the commercialization narrative.
Price Chart
Executive Summary
Humacyte announced positive top-line interim results from the V012 Phase 3 study of its acellular tissue engineered vessel (ATEV) in female dialysis patients. The study met its primary endpoint with a statistically significant increase in catheter-free days (average 220 vs. 129 days, p=0.00070), prompting early enrollment termination. The company plans to file a supplemental BLA with the FDA in the second half of 2026 for a label expansion targeting adult end-stage kidney disease patients at risk of AV fistula maturation failure.
Key Facts
- V012 Phase 3 interim analysis (80 patients) met primary endpoint: ATEV patients averaged 220 catheter-free days vs. 129 days for AV fistula (p=0.00070).
- Infections rate: 6 per 100 patient years for ATEV vs. 23 per 100 patient years for AV fistula; no access-associated infections in ATEV group.
- Study enrollment terminated early per protocol; 120 patients currently enrolled out of planned 150.
- Humacyte to file supplemental BLA with FDA in H2 2026 for dialysis access indication in high-risk patients.
- ATEV already approved (December 2024) for extremity vascular injury; this readout targets a much larger dialysis population (nearly 500,000 U.S. hemodialysis patients).
- Results to be presented June 11, 2026 at Society for Vascular Surgery Annual Meeting.
Financial Impact
Label expansion to dialysis access could significantly expand addressable market beyond current vascular trauma indication. No revenue figures disclosed.
Risk Factors
- Supplemental BLA remains subject to FDA review; approval not guaranteed.
- Competition from existing dialysis access methods (AV fistulas, grafts, catheters).
- Company is still early in commercial ramp for existing indication; cash burn may persist.
- The interim analysis was on first 80 of 120 patients; full dataset may differ.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3310082 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | Press Release | $0.4400 | awaiting T+60 | — | $0.4571 (+3.89%) |
Aug 19, 2026 9w ago | Press Release | $0.7349 | awaiting T+60 | — | $0.4571 (−37.80%) |
Aug 12, 2026 10w ago | 8-K | $0.6650 | awaiting T+60 | — | $0.4571 (−31.26%) |
Aug 12, 2026 10w ago | Press Release | $0.6650 | awaiting T+60 | — | $0.4571 (−31.26%) |
Aug 7, 2026 11w ago | Press Release | $0.7180 | awaiting T+60 | — | $0.4571 (−36.34%) |
Jun 12, 2026 19w ago | Institutional Cluster | $1.06 $0.5790 | ▼ −45.12% | ▼ −47.90% | $0.4571 (−56.67%) |
Jun 11, 2026 19w ago | 8-K | $1.06 $0.5790 | ▲ +45.12% | ▲ +47.90% | $0.4571 (+56.67%) |
Jun 10, 2026 19w ago | Press Release | $1.08 $0.5949 | ▲ +44.92% | ▲ +48.74% | $0.4571 (+57.68%) |
Jun 10, 2026 19w ago | Press Release | $1.08 $0.5949 | ▲ +44.92% | ▲ +48.74% | $0.4571 (+57.68%) |
Jun 10, 2026 19w ago | Press Release | $1.08 $0.5949 | ▼ −44.92% | ▼ −48.74% | $0.4571 (−57.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers